Machine Learning for Identifying Adverse Drug Events

用于识别药物不良事件的机器学习

• 批准号: 8274647
• 负责人: C DAVID PAGE, JR.
• 金额: $ 53.73万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-10 至 2014-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8274647
• 关键词: Address; Adverse event; Adverse reactions; Algorithms; Area Under Curve; Classification; Clinic; Clinical; Code; Computerized Medical Record; Congresses; Data; Data Analyses; Data Set; Decision Trees; Diagnosis; Event; Foundations; Future; Genetic Crossing Over; Goals; Health; Hemorrhage; Institute of Medicine (U.S.); Learning; Left; Life; Machine Learning; Marketing; Measures; Medical; Methodology; Methods; Modeling; Myocardial Infarction; Outcome; Patients; Performance; Pharmaceutical Preparations; ROC Curve; Recording of previous events; Research Priority; Risk; Sensitivity and Specificity; Sentinel; Specificity; Subgroup; Supervision; System; Testing; Training; United States Agency for Healthcare Research and Quality; United States National Institutes of Health; Validation; Warfarin; Work; base; computer based statistical methods; cost; data mining; improved; inhibitor/antagonist; novel; novel strategies; patient safety; post-market; software systems; standard measure; tool; vector

DESCRIPTION (provided by applicant): Because of the direct effect on patient safety, the FDA, AHRQ and Institute of Medicine have flagged post- marketing pharmacovigilance of emerging medications as a high national research priority. The FDA, Foundation for the NIH and PhARMA have formed the Observational Medical Outcomes partnership to develop and compare methods for identification of adverse drug events (ADEs), and the FDA has announced its Sentinel Initiative. The proposed work will develop and study machine learning for ADE identification and prediction. The latter, easier task of ADE prediction assumes that an ADE has already been identified -- such as the association between Cox2 inhibitors (Cox2ib) and myocardial infarction (MI) - and the goal is to construct a model that can accurately predict which patients are most susceptible to having the ADE, e.g., having an MI if they take a Cox2 inhibitor. Our preliminary results show that using machine learning we can already make predictions at 75% sensitivity with 75% specificity. The task of ADE identification is more difficult than ADE prediction, because we do not have an observed class variable. Given that a new drug has been placed on the market, this task seeks to determine whether any previously-unanticipated adverse event is caused by the drug. Because we do not know in advance what this event is - it may not even correspond to an existing diagnosis code - this task does not neatly fit into the standard supervised learning paradigm. Our approach is to use reverse machine learning to build a post- marketing surveillance tool in order to predict and/or detect adverse reactions to drugs from electronic medical records (EMRs) or claims data. We show both theoretically and with preliminary empirical results that this approach can discover one or more subgroups of patients who are characterized by previously-unanticipated adverse events - events that patients on the drug suffer at a higher rate than patients not on the drug. These events do not have to correspond to previously-defined ADEs. In order to build and evaluate a machine learning-based system for ADE identification and prediction, this proposal will address the following specific aims: (1) apply supervised machine learning to the task of ADE prediction - predicting which patients are most likely to suffer a known ADE if given the drug; (2) apply reverse machine learning to identify novel ADEs; (3) provide a complete software system for machine learning-based identification and prediction of ADEs. This system will be tested on both the Marshfield Clinic's EMR, some preliminary results of which are presented in this proposal, and on real and synthetic datasets available through the Observational Medical Outcomes Partnership (OMOP).

描述（由申请人提供）：由于对患者安全性的直接影响，FDA、AHRQ和医学研究所已将新兴药物的上市后药物警戒标记为国家研究优先事项。FDA、NIH基金会和PhARMA已经建立了观察性医学结果伙伴关系，以开发和比较药物不良事件（ADE）的识别方法，FDA已经宣布了其哨兵计划。拟议的工作将开发和研究用于ADE识别和预测的机器学习。后者，ADE预测的更容易的任务假设ADE已经被识别-例如Cox 2抑制剂（Cox 2 ib）和心肌梗死（MI）之间的关联-目标是构建一个模型，可以准确预测哪些患者最容易发生ADE，例如，如果他们服用Cox 2抑制剂就会患心肌梗死。我们的初步结果表明，使用机器学习，我们已经可以以75%的灵敏度和75%的特异性进行预测。ADE识别的任务比ADE预测更困难，因为我们没有观察到的类变量。鉴于一种新药已经上市，这项任务旨在确定任何先前未预料到的不良事件是否由该药物引起。因为我们事先不知道这个事件是什么-它甚至可能不对应于现有的诊断代码-这个任务并不完全适合标准的监督学习范式。我们的方法是使用反向机器学习来构建上市后监督工具，以便从电子病历（EMR）或索赔数据中预测和/或检测药物的不良反应。我们从理论上和初步的经验结果表明，这种方法可以发现一个或多个亚组的患者谁是以前未预料到的不良事件的特点-事件的患者遭受的药物比患者更高的利率不对药物。这些事件不必对应于先前定义的ADE。为了构建和评估用于ADE识别和预测的基于机器学习的系统，该提案将解决以下具体目标：（1）将监督机器学习应用于ADE预测任务-预测哪些患者在给予药物后最有可能遭受已知ADE;（2）应用反向机器学习来识别新型ADE;（3）为基于机器学习的ADE识别和预测提供完整的软件系统。该系统将在马什菲尔德诊所的EMR上进行测试，其中一些初步结果在本提案中提出，并通过观察性医疗成果伙伴关系（OMOP）在真实的和合成数据集上进行测试。